| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (AstraZeneca) D081DC00007 / PROFOUND | A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound, D081DC00007) | Hotte, Dr Sebastien | Open | NCT02987543 |
| (BMS) CA018005 / FRACTION-RCC | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma | Hotte, Dr Sebastien | Open | NCT02996110 |
| (BMS) CA2099KD / CheckMate 9KD | A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD) | Hotte, Dr Sebastien | Open | NCT03338790 |
| (CCTG) IND.232 | A Phase II Study of Durvalumab With or Without Tremelimumab in Patients With Metastatic castration Resistant Prostate Cancer | Hotte, Dr Sebastien | Open | NCT02788773 |
| (CCTG) IND.234 / PC-BETS - Master Protocol | Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol | Mukherjee, Dr Som | Open | NCT03385655 |
| (CCTG) IND.234 / PC-BETS - Sub-Study A | A Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open | NCT03385655 A |
| (CCTG) IND.234 / PC-BETS - Sub-Study B | A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open | NCT03385655 B |
| (CCTG) IND.234 / PC-BETS - Sub-Study C | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open | NCT03385655 C |
| (CCTG) IND.234 / PC-BETS - Sub-Study IND.223 | A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open | NCT02905318 |
| (Clovis) CO-338-052 / TRITON2 | A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency | Hotte, Dr Sebastien | Open | NCT02952534 |
| (JCC) Prostate HBI | Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer | Dayes, Dr Ian | Open | NCT03196778 |
| (JGH) PCS IX / PCS 9 | The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: An Adaptive Phase II/III Randomized Trial. | Tsakiridis, Dr Theos | Open | NCT02685397 |
| (Roche) CO39303 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC, PREVIOUSLY UNTREATED, METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | Mukherjee, Dr Som | Open | NCT03072238 |
| OCOG-2013-PETMUSE | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | Mukherjee, Dr Som | Open | NCT02462239 |
| OCOG-2016-MISTER | Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel PET Radiotracers in Castration-Resistant Prostate Cancer | Hotte, Dr Sebastien | Open | NCT02813226 |
| (Agensys) AGS-16C3F-15-3 | A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | Hotte, Dr Sebastien | On hold | NCT02639182 |
| (AstraZeneca) D933IC00003 / BAYOU | A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineligible Patients With Unresectable Stage IV Urothelial Cancer | Mukherjee, Dr Som | On hold | NCT03459846 |
| (UHN) TOPCOP | TOward Personalizing Care for Older men with mCRPC - understanding and predicting treatment toxicities (the TOPCOP study) | Hotte, Dr Sebastien | On hold | NCT02512185 |
Find a Trial
Contact Us